Drug Overview
Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disorder. Fluticasone furoate is an inhaled corticosteroid that activates the glucocorticoid response element and inhibits pro-inflammatory transcription factors such as NF?B, and antigen-induced lung eosinophilia, thereby suppressing inflammation. Vilanterol is a long-acting beta 2 agonist that stimulates intracellular adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate to cyclic-3’,5’-adenosine monophosphate (AMP). Increased levels of cyclic AMP result in the relaxation of bronchial smooth muscles and inhibition of the release of mediators of immediate hypersensitivity from mast cells.
Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disorder. Fluticasone furoate is an inhaled corticosteroid that activates the glucocorticoid response element and inhibits pro-inflammatory transcription factors such as NF?B, and antigen-induced lung eosinophilia, thereby suppressing inflammation. Vilanterol is a long-acting beta 2 agonist that stimulates intracellular adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate to cyclic-3’,5’-adenosine monophosphate (AMP). Increased levels of cyclic AMP result in the relaxation of bronchial smooth muscles and inhibition of the release of mediators of immediate hypersensitivity from mast cells.
Note: Product cover images may vary from those shown
1 Product Profiles
Figure 52: The author’s drug assessment summary of Xolair in asthma
Figure 53: The author’s drug assessment summary of Xolair in asthma
Figure 54: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: Breo Ellipta for asthma - SWOT analysis
Figure 5: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 6: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 7: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Breo drug profile
Table 2: Phase III trial data for Breo in COPD
Table 3: Breo late-phase trial data in COPD
Table 4: Breo Ellipta drug profile
Table 5: Breo Ellipta pivotal trial data in asthma
Table 6: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 7: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
- Breo: Chronic obstructive pulmonary disease (COPD)
- Breo Ellipta: Asthma
Figure 52: The author’s drug assessment summary of Xolair in asthma
Figure 53: The author’s drug assessment summary of Xolair in asthma
Figure 54: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: Breo Ellipta for asthma - SWOT analysis
Figure 5: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 6: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 7: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Breo drug profile
Table 2: Phase III trial data for Breo in COPD
Table 3: Breo late-phase trial data in COPD
Table 4: Breo Ellipta drug profile
Table 5: Breo Ellipta pivotal trial data in asthma
Table 6: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 7: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
- GlaxoSmithKline
- Innoviva
Note: Product cover images may vary from those shown
